Source: Benzinga

Zosano Pharma: Zosano Pharma Investors Who Have Suffered Losses Greater Than $50,000 Encouraged To Contact Kehoe Law Firm, P.C.

PHILADELPHIA, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Zosano Pharma Corporation (NASDAQ:ZSAN) to determine whether the Company engaged in securities fraud or other unlawful business practices.Zosano investors who purchased, or otherwise acquired, the Company's securities and suffered losses greater than $50,000 are encouraged to complete Kehoe Law Firm's Securities Class Action Questionnaire or contact Kevin Cauley, Director, Business Development, (215) 792-6676, Ext. 802, [email protected], [email protected], to discuss the securities investigation or potential legal claims.On September 30, 2020, Zosano disclosed that it ". . . received a discipline review letter ('DRL') from the U.S. Food and Drug Administration ('FDA') in connection with the Qtrypta (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug ...Full story available on Benzinga.com

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Steven Lo's photo - President & CEO of Zosano Pharma

President & CEO

Steven Lo

CEO Approval Rating

83/100

Zosano Pharma is a clinical-stage biopharmaceutical company that researches, develops and commercializes novel therapeutics to treat migraines. Read more